IMFINZI-subQSafety and Pharmacokinetics of Subcutaneous Durvalumab in Adults with Solid Tumours

This study is a Phase I trial happening across multiple locations, focusing on the treatment of solid tumors in adults. The study has two parts: Dose Escalation and Dose Expansion. The first part involves patients with specific types of cancer, including non-small cell lung cancer, hepatocellular carcinoma, or limited-stage small cell lung cancer. This part will test two planned dose levels of a drug called Durvalumab, given subcutaneously (under the skin). The main goal is to understand how this drug behaves in the body and evaluate its safety. The second part of the study will include patients with unresectable hepatocellular carcinoma, and will begin once a suitable dose has been identified from the first part. During the study, participants will receive Durvalumab through subcutaneous injections. The study measures the results by looking at two primary outcomes: the area under the concentration-time curve (AUC) and the observed lowest concentration before the next dose is administered (Ctrough). These measurements help researchers understand how Durvalumab is processed by the body over time and between doses. This information is crucial to determine the appropriate dosing and administration for future use.